Literature DB >> 25648910

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

Hassan Izzedine1, Mark A Perazella2.   

Abstract

A bidirectional relationship has been observed for kidney disease and cancer. On the one hand, cancer is an important complication noted in kidney disease as well as a major cause of morbidity and mortality in this group. On the other hand, improved cancer treatment has prolonged survival, but also increased the development of acute and chronic kidney disease. The combination of cancer and kidney disease makes it challenging for clinicians to provide comprehensive and safe therapies for this group of patients. As such, clinicians caring for this group must develop expertise and become competent in the practice of a newly evolving subspecialty of nephrology known as 'onco-nephrology'. This brief narrative review will focus on the cancer risk in patients with underlying kidney disease, the therapies such as erythropoiesis-stimulating agents on cancer progression and other outcomes, and the appropriate dosing of anti-cancer agents in patients with underlying kidney disease.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  albuminuria; cancer; dosage adjustment; erythropoiesis-stimulating agents; kidney disease

Mesh：

Substances：

Year:  2015        PMID： 25648910      PMCID： PMC4832985          DOI： 10.1093/ndt/gfu387

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


  105 in total

1.  Transforming growth factor-beta1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells.

Authors:  Michael Gekle; Petra Knaus; Rikke Nielsen; Sigrid Mildenberger; Ruth Freudinger; Verena Wohlfarth; Christoph Sauvant; Erik I Christensen
Journal:  J Physiol       Date:  2003-10-15       Impact factor: 5.182

2.  Breast cancer trial with erythropoietin terminated unexpectedly.

Authors:  Brian Leyland-Jones
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

3.  Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats.

Authors:  Sihem Ait-Oudhia; Jean-Michel Scherrmann; Wojciech Krzyzanski
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

4.  Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans.

Authors:  P J Stohlawetz; L Dzirlo; N Hergovich; E Lackner; C Mensik; H G Eichler; E Kabrna; K Geissler; B Jilma
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

5.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

Authors:  Brian Leyland-Jones; Vladimir Semiglazov; Marek Pawlicki; Tadeusz Pienkowski; Sergei Tjulandin; George Manikhas; Antoly Makhson; Anton Roth; David Dodwell; Jose Baselga; Mikhail Biakhov; Konstantinas Valuckas; Edouard Voznyi; Xiangyang Liu; Els Vercammen
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

6.  Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review.

Authors:  J J Caro; M Salas; A Ward; G Goss
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

7.  The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis.

Authors:  Maggie K M Ma; Wai H Lim; Robin M Turner; Jeremy R Chapman; Jonathan C Craig; Germaine Wong
Journal:  Transplantation       Date:  2014-12-27       Impact factor: 4.939

8.  September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.

Authors:  Matti S Aapro; Hartmut Link
Journal:  Oncologist       Date:  2008

9.  Cancer risk following organ transplantation: a nationwide cohort study in Sweden.

Authors:  J Adami; H Gäbel; B Lindelöf; K Ekström; B Rydh; B Glimelius; A Ekbom; H-O Adami; F Granath
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

Review 10.  Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

Authors:  Catherine K Yeung; Danny D Shen; Kenneth E Thummel; Jonathan Himmelfarb
Journal:  Kidney Int       Date:  2013-10-16       Impact factor: 10.612
View more
  10 in total

1.  Cancer risk in patients receiving renal replacement therapy: A meta-analysis of cohort studies.

Authors:  Weifeng Shang; Liu Huang; Li Li; Xiaojuan Li; Rui Zeng; Shuwang Ge; Gang Xu
Journal:  Mol Clin Oncol       Date:  2016-07-07

2.  The association of preoperative reduced glomerular filtration rate with higher staging and histology grades in patients with urinary tract cancers.

Authors:  Vedran Premuzic; Tvrtko Hudolin; Luka Penezic; Ines Golubic; Marija Gamulin; Bojan Jelakovic; Zeljko Kastelan
Journal:  Int Urol Nephrol       Date:  2019-06-24       Impact factor: 2.370

3.  Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma.

Authors:  Tetsushi Murakami; Eiji Kikuchi; Hiroki Ide; Yuta Umezawa; Takayuki Takahashi; Mizuki Izawa; Kyohei Hakozaki; Keisuke Shigeta; Koichiro Ogihara; Hiroaki Kobayashi; Kunimitsu Kanai; Takahiro Maeda; Shunsuke Yoshimine; Ryuichi Mizuno; Koshiro Nishimoto; Mototsugu Oya
Journal:  BJUI Compass       Date:  2021-03-09

4.  The association of the decline in glomerular filtration rate with aggressive endometrial cancers.

Authors:  Vedran Premuzic; Egon Kruezi; Matea Berovic; Lana Leko; Lucija Susnjar; Ingrid Marton; Drazan Butorac; Dubravko Habek
Journal:  Int Urol Nephrol       Date:  2019-11-01       Impact factor: 2.370

5.  Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study.

Authors:  Jui-Kun Chiang; Lin Chih-Wen; Yee-Hsin Kao
Journal:  BMJ Open       Date:  2017-06-23       Impact factor: 2.692

Review 6.  Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome.

Authors:  Simona Mihai; Elena Codrici; Ionela Daniela Popescu; Ana-Maria Enciu; Lucian Albulescu; Laura Georgiana Necula; Cristina Mambet; Gabriela Anton; Cristiana Tanase
Journal:  J Immunol Res       Date:  2018-09-06       Impact factor: 4.818

7.  Risk of cancer in pre-dialysis chronic kidney disease: A nationwide population-based study with a matched control group.

Authors:  Sehoon Park; Soojin Lee; Yaerim Kim; Yeonhee Lee; Min Woo Kang; Kyungdo Han; Seoung Seok Han; Hajeong Lee; Jung Pyo Lee; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Dong Ki Kim
Journal:  Kidney Res Clin Pract       Date:  2019-03-31

8.  Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study.

Authors:  Rajkumar Chinnadurai; Emma Flanagan; Gordon C Jayson; Philip A Kalra
Journal:  BMC Nephrol       Date:  2019-10-22       Impact factor: 2.388

9.  The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation.

Authors:  Shaan Dudani; Horia Marginean; Joanna Gotfrit; Patricia A Tang; Jose Gerard Monzon; Kristopher Dennis; Hagen F Kennecke; Erin D Powell; Sam Babak; Winson Y Cheung; Michael M Vickers
Journal:  Dis Colon Rectum       Date:  2021-12-01       Impact factor: 4.585

10.  Decreased Preoperative Estimated Glomerular Filtration Rate Was Related With Poor Prognosis of NSCLC Patients.

Authors:  Wenqiao Jia; Cong Wang; Yufeng Cheng
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.